Healthcare Pitch Deck Examples: Four Real Decks and What Made Them Raise

TL;DR

Healthcare pitch decks carry a harder brief than most: multiple stakeholders, regulated markets, and technically dense products that need to land with investors who may not be clinical experts. The four healthcare pitch deck examples in this post show how founders at different stages solved that problem.

• Problem slides built from external evidence (press, statistics, published research) consistently outperform self-described problem framing
• Credibility signals should be stage-matched: payer contracts at seed, benchmarks at pre-seed, scale metrics at Series C and beyond
• The reimbursement question rarely gets a dedicated slide; the decks that raise find ways to answer it without being asked
• Clinical framing and product narrative can substitute for traction when traction is not yet available

Healthcare is one of the most funded verticals in technology right now, and also one of the hardest to pitch well. These healthcare pitch deck examples make that clear: a founder in this space has to hold several audiences in mind simultaneously — the clinician who uses the product, the payer who authorizes it, the health system that procures it, and the investor sitting across the table who may have deep expertise in none of these. Getting all four right, in fifteen slides, is a different kind of problem than most decks solve.

We've been building healthcare and digital health pitch decks for over twelve years at Whitepage. In that time, we've worked on 1,000+ projects with teams that have collectively raised over $1.5B. The question we hear most often is some version of: "Can you show me what a good healthcare deck actually looks like?"

So instead of a template, here are four real decks worth studying, pulled apart by structure and narrative decision rather than outcome alone.

The Funding Climate That Shapes This Brief

U.S. digital health startups raised $14.2 billion in 2025, up 35% from $10.5 billion in 2024, according to Rock Health. That recovery looks encouraging on the surface, but the distribution tells a more specific story: nearly 40% of that capital landed in mega-rounds, and 42% of total funding went to companies working on healthcare workflow and operational tools — clinical documentation, revenue cycle management, care coordination infrastructure.

‍

‍

Medtech followed a similar trajectory. J.P. Morgan's Q2 2025 report tracked $6.8 billion in medtech venture funding in the first half of 2025 alone, putting the sector on pace to surpass its full-year 2024 total.

The pattern emerging across both categories is selectivity. Investors are still writing large checks, but increasingly for companies that solve urgent, measurable operational pain inside healthcare delivery and can demonstrate it early. For a founder building a medical device pitch deck or a health tech pitch deck today, that selectivity raises the stakes on every structural decision.

What this means in practice: the healthcare investor reading your deck already believes the problem is real. They're asking whether you understand the system well enough to solve it, and whether you've anticipated the objections they're holding before they ask.

‍

‍

Four Healthcare Pitch Deck Examples, Broken Down by Stage

Flo raised $200M at Series C. Jimini raised $8M at Pre-Seed. Hopscotch raised $8M at Seed. Crosby Health raised $2.2M at Pre-Seed. Different stages, different sub-verticals, different investor audiences. What they share is more instructive than what separates them.

Flo — $200M Series C, Consumer Digital Health

Flo's deck opens with a single defining number: 1 out of 4 women in the U.S. uses Flo. Not a market size. Not a category definition. A penetration claim that establishes category leadership before any context is provided.

The market slide then makes a structural move that carries the entire investment thesis. Rather than presenting one TAM figure, the deck positions Flo at the intersection of three converging markets: FemTech ($60B at 9% CAGR), Digital Health ($180B at 25% CAGR), and Consumer Subscription (projected 29% growth over three years). The visual is a Venn diagram, but the logic is an argument. Flo's moat is the overlap between three growing categories that no single competitor occupies simultaneously. The market slide and the defensibility slide are doing the same job at the same time.

The investment highlights slide sequences its five points deliberately: scale (70M+ monthly active users, 5M+ paying subscribers), competitive moat (medically verified content, personalization, feature depth), monetization path, profitability milestone (EBITDA positive in 2024, cash flow positive today), and team — in that order. The deck moves from proof of scale to proof of economics before it arrives at the team, the reverse of how many founders instinctively structure their pitch.

Here's why that matters: at Series C, the deck's job is not to introduce the company. It's to make the investment thesis obvious.

The intersection-of-markets framing accomplishes this faster than a conventional TAM/SAM/SOM slide, and the investment highlights sequencing leaves the investor with a fully formed economic argument before the ask.

Rock Health's 2025 data shows capital concentrated in companies with demonstrated category leadership. Flo's deck performs that proof structurally, not just through claims.

Jimini — $8M Pre-Seed, Digital Mental Health

Jimini raised $8M at pre-seed, a stage where traction is thin and clinical proof is rarely available. The deck solves this constraint by making the product story carry the credibility weight that data cannot yet provide.

The opening is a research chart showing that therapy outcomes have not materially improved in decades. Not a market size number. A clinical stagnation argument, sourced from published research. This framing tells investors something specific: the problem isn't simply that the market is underserved at the distribution level. It's broken at the product level. That's a harder problem to solve, and a more defensible one to own.

The product section then uses two consecutive slides to build a clinical proof-of-concept narrative without clinical data. "Deeper Understanding Enables Hope and Confidence" shows how the AI gathers client context before the first therapy session, enabling therapists to set goals faster and with more precision. "Continuous Support Drives Clinical Progress" shows the proactive and reactive care model, with 24/7 AI access between sessions alongside provider-led activities. Together, these slides read like a clinical protocol. The product isn't described as a consumer app. It's described as a care delivery system with measurable clinical logic.

Tip: the clinical slide is not a text slide. A benchmark score like 91.8% belongs in a comparison graphic, not a sentence. A care pathway belongs in a flow, not a paragraph. The data is usually strong — the presentation just has to match it.

The appendix section devoted to published science is the most unusual structural choice in the deck. Four academic studies. Methodology notes. Evidence design. At pre-seed, this material is almost never included. It signals that the founders understand clinical rigor at a level most early-stage health tech decks don't reach.

The key takeaway: when traction is limited, clinical framing and research depth can carry the credibility weight.

This connects directly to what a16z's Julie Yoo has observed about seed-stage healthcare investing — investors look for founders with "highly opinionated answers" on why previous approaches in the category failed. Jimini's opening (therapy hasn't improved in decades, and here is the evidence) is exactly that argument, embedded in the deck's structure before the product is introduced.

‍

‍

Hopscotch — $8M Seed, Pediatric Behavioral Health

Hopscotch's deck opens with four statistics establishing the scale of the pediatric behavioral health crisis: 20% of children have a diagnosable mental health condition, 80% go without care, 75% of providers report being at capacity, and 20% of pediatricians name mental health as the most pressing issue they face. This is followed immediately by a press coverage slide aggregating headlines from Hospital Review, Children's Health Defense, and Science magazine, titled "The crisis is getting worse by the day."

Before Hopscotch introduces itself, the investor has already seen two full slides of external, named evidence establishing urgency. The product appears only after the problem has been proved.

The insight slide then delivers the deck's thesis: the solution to the pediatric behavioral health crisis isn't simply increasing access to more providers. It's improving the quality of care by giving providers better tools to support the entire family. This reframes the company from a capacity play to a quality and defensibility play. It's a stronger investor argument, and a more specific moat.

The reimbursement slide near the end of the deck deserves particular attention. It shows the logos of eight payers — Aetna, United, Cigna, BlueCross, Oscar, Magellan, Highmark, Empire — negotiated before the Series A round. No explanatory text. No market sizing of the reimbursement landscape. Just the logos.

This is one of the most effective structural moves available to a seed-stage healthcare founder. It answers the payment objection before the investor asks it, and it signals a level of operational progress that changes how the rest of the deck is read.

The key takeaway: external validation does more credibility work than product slides at the seed stage.

The payer wall is worth building early. If you're building a digital health pitch deck for behavioral health, care delivery, or any category that touches insurance reimbursement, showing negotiated payer relationships pre-empts the question every healthcare investor is holding silently.

Crosby Health — $2.2M Pre-Seed, Health Tech / AI Infrastructure

Crosby Health builds AI tooling to automate medical billing denial appeals. The deck opens with mainstream news headlines: lawsuits alleging that major insurers used AI to deny medically necessary claims. No explanation. No context slide. The problem is introduced through public-record evidence the investor already recognizes.

The next slide quantifies the economics directly: providers spend $20 billion to appeal denials, and only $10 billion is actually overturned. The gap is the market. This isn't an abstract TAM calculation. It's a recoverable loss number, and it positions the investment as a recapture opportunity rather than a greenfield bet.

The clinical LLM benchmark slide is one of the more distinctive technical credibility approaches in recent pre-seed health tech decks. ApolloLLM scores 91.8% on the MedQA Medical Exam Benchmark, compared to Med-PaLM 2 at 86.5% and the average medical student at 60%. Third-party benchmarks are more common in AI startup pitch decks, but relatively rare in health tech at pre-seed. Here, the benchmark substitutes for clinical validation that doesn't yet exist. It tells investors the technology is real and measurable without requiring a pilot or deployment.

The product section then grounds this with a dashboard screenshot showing $130,356 in revenue recovered across 37 appeals in seven days. At pre-seed, that kind of early proof — concrete, specific, not projected — lands differently than a revenue growth curve.

The key takeaway: for a medical device pitch deck or health tech deck at pre-seed, benchmarks and early revenue screenshots replace traction slides.

The goal is to show the technology works and the economics are directionally correct. This is the pre-seed version of the same pattern that later-stage companies like Abridge ($250M Series D, 100+ health system deployments) and Suki ($70M Series D, EHR integrations with Epic, Oracle, and Meditech) demonstrate at scale: show the machine working in a real environment before projecting where it goes.

The Structural Patterns These Healthcare Pitch Deck Examples Share

Looking across all four decks, several patterns appear regardless of stage or sub-vertical.

‍

Problem slides open with external evidence, not internal claims. All four decks establish the urgency of their problem through data, headlines, published research, or third-party statistics before introducing the company. The founder's product appears only after the investor already believes the problem is real. This sequencing is consistent across every stage represented here.

Credibility is calibrated to stage. Flo uses scale (70M monthly active users). Crosby uses a benchmark score. Jimini uses published academic research. Hopscotch uses payer contracts. Each deck finds the appropriate proof signal for its moment. None reaches for metrics it doesn't have. Stage-appropriate credibility reads as honest. Overreach reads as a signal to dig harder.

The "why now" argument is embedded, not stated. None of these decks include a standalone "Why Now" slide. The timing argument is built into the problem framing: a pediatric behavioral crisis worsening by the day, insurers using AI to deny medically necessary care, therapy outcomes stagnant for decades. The urgency lives in the evidence.

Reimbursement and payment logic appear early. Hopscotch's payer wall is the clearest example, but Crosby's billing economics and Jimini's clinical evidence design serve equivalent functions for their respective investor audiences. The decks that perform well answer the payment question structurally, rather than waiting for a diligence conversation.

The ask lands after a complete argument. By the time these decks reach the investment highlights or use of funds slide, the investor has already been walked through the clinical, operational, and market logic. The fundraising ask carries more weight when it follows that sequence.

How to Build Your Own Healthcare Pitch Deck Using These Patterns

The four examples above point toward a slide sequence that consistently de-risks the questions healthcare investors carry. It isn't a rigid template, but the structure below reflects what appears across the decks that raise.

‍

1. ‍Problem (with external evidence). Statistics, published research, or press headlines. For a medical device pitch deck, clinical prevalence data works well. For digital health, operational or economic inefficiency data tends to land faster.

1. Why now (embedded in context). Policy shifts, labor shortages, AI capability, cost pressure. Frame it as context woven into the problem, not a standalone slide.
2. Insight or thesis slide. Your contrarian framing that redefines the category. Not "we're building X for healthcare," but "the previous approach to this problem was structurally limited, and here's why."
3. Product and workflow fit. Show exactly where your product sits in the care delivery chain. For technically complex products, the deep tech pitch deck framework is useful here, particularly for medical device founders who need to explain architecture to a non-clinical investor.
4. Clinical validation or evidence plan. At pre-seed: published science, benchmarks, or pilot design. At seed: early outcomes data or case examples. At Series A and beyond: clinical studies, peer-reviewed results, or deployment metrics at scale.
5. Regulatory path. For medical device founders: FDA clearance pathway, current status, and timeline. Its absence reads as a gap to investors who regularly back this category.
6. Reimbursement and payment logic. Payer logos outperform explanations. If you have negotiated relationships, show them.
7. Traction (stage-matched). Early revenue, deployment screenshots, payer contracts, or benchmark scores rather than projected curves.
8. Financial projections. Build these assumption-driven, not just outcome-driven. Investors want to see the logic behind the numbers. Here's how we approach financial projections in pitch decks for early-stage companies.
9. Use of funds. Specific, milestone-tied, connected back to the narrative. A guide to structuring the use of funds slide is worth reviewing before building this one.
10. Team. Clinical credentials, operator experience, and technical depth. Healthcare investors look for all three. A team with deep clinical knowledge but no operator background reads as a product risk. A team with strong engineering credentials but no clinical advisors raises adoption questions.

Tip: Slides that need three paragraphs to make sense usually have a narrative problem, not a design problem. Before you try to design a complex slide, ask: what is the one thing I want someone to take away from this? If you can't answer that in one sentence, the design work hasn't started yet.

The founders who come to us building healthcare decks are almost always the most technically fluent people we work with. The challenge is rarely knowledge. It's translation: taking what you understand at depth and making it legible to someone who has twenty minutes and a portfolio of forty companies. That's a craft problem, and it's a solvable one. The decks above solved it in very different ways depending on what they had available at their stage. What they shared was a willingness to show the hard thinking had already been done. For a broader look at the funding dynamics shaping investor expectations right now, this overview of AI startup funding trends is a useful starting point before you build.

Let's talk about your deck.

‍